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Our findings emphasize the importance of a multidimensional approach to PRO assessment to most 
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Patient-reported Outcome (PRO) measures used in cancer research can assess a number of health 
domains. Our primary objective was to investigate which broad types of PRO domains, Functional 
health, Symptoms, and Global Quality of Life (QoL), most frequently yield significant differences 
between treatments in randomized controlled trials (RCTs). 
Methods 
Two-hundred-twenty-nine RCTs published between January 2004 and February 2019, conducted on 
patients diagnosed with most common solid malignancies, and using the EORTC QLQ-C30 
questionnaire were considered. Studies were identified systematically using literature searches in 
key electronic databases. Unlike other PRO measures typically used in RCTs, the scoring algorithm 
of the multidimensional EORTC QLQ-C30 allows to clearly distinguish the three broad types of 
PRO domains. 
Results 
One hundred thirty-four RCTs (58·5%) reported statistically significant differences between 
treatment arms for at least one of the QLQ-C30 domains. Most frequently differences were reported 
for two or all three broad types of PRO domains (78 of 134 trials, 58·2%). In particular, 35 trials 
(26·1%), found significant differences for Symptoms, Functional health, and Global QoL, 24 trials 
(17·9%) for Symptoms and Functional health, 11 trials (8·2%) for Functional health and Global 
QoL, and 8 trials (6·0%) for Symptoms and Global QoL. The likelihood of finding a statistically 
significant difference between treatment arms was not associated with key study characteristics, 
such as study design (i.e., open-label vs. blinded trials) and industry support. 
Conclusions 
Our findings emphasize the importance of a multidimensional PRO assessment to most 









• Whilst there is convincing evidence of the value of assessing Patient-Reported Outcomes 
(PROs) in oncology, there is now ample discussion on “which” PROs should actually be 
measured in cancer clinical trials. Indeed, PRO measures can assess a number of health 
domains ranging from individual symptoms to broader health domains, such as functional 
status and quality of life (QoL). 
 
• We analyzed 229 randomized controlled trials (RCTs) published over the last 15 years 
conducted in patients diagnosed with most common solid cancer malignancies, which have 
used the multidimensional EORTC QLQ-C30 questionnaire to assess treatment differences. 
This PRO measure allows to distinguish the following three broad types of PRO domains: 
Functional health, Symptoms, and Global QoL. We found that in most trials, differences are 
typically reported for combinations of functional health, symptoms, and Global QoL.  
 
• Our findings emphasize the importance of a multidimensional approach to PRO assessment 
in cancer clinical trials to most comprehensively capture the overall burden of therapy from 







Major progress has been made in the treatment of cancer, with a remarkable number of new drugs 
approved since 2012 by the European Medicines Agency (EMA) and the US Food and Drug 
Administration (FDA)1. Many of these clinical achievements stem from randomized controlled 
trials (RCTs) that are considered the gold standard with which healthcare professionals and policy-
makers make decisions regarding treatment efficacy2.  
The number of RCTs that include patient-reported outcomes (PROs)3 has increased substantially 
over the last 20 years4, reflecting their general gain in importance in oncology, also from a 
regulatory standpoint5-7. However, PRO measures can assess a number of health domains ranging 
from individual or clusters of symptoms (e.g. pain, fatigue, nausea), to functional domains (e.g. 
physical or social function) and even broader concepts such as general health status and health-
related quality of life (HRQoL)8,9. The latter is a multi-dimensional concept that the EMA has 
defined as the patient’s subjective perception of the impact of disease and treatment on daily life, 
physical, psychological and social functioning and well-being10.  
Responding to the increased use of PROs as endpoints in cancer clinical trials, the FDA3 and 
EMA10 have published guidance documents providing a regulatory perspective on PRO 
measurement.  This has also led to extensive discussion about what domains of PROs are the most 
relevant endpoints in cancer RCTs1,11-13.  
In 2014 a major international initiative led by the U.S. National Cancer Institute (NCI) emphasized 
the need to harmonize PRO outcome measurement across studies and proposed the use of a core set 
of symptoms across all trials14. Others, have suggested that, in the RCT setting, limiting PRO 
assessment to symptom endpoints “may provide outcome data sufficient to make decisions about 
the value of a therapy or to allow judgment about the relative value of one therapy contrasted with 
another”15. More recently, FDA representatives12,16,17 have recommended to consider physical 
 
 
function, symptomatic adverse events and disease-related symptoms as a starting point for defining 
patient-reported endpoints in cancer trials, while encouraging to measure also other aspects of 
patient experience18 and to define core clinical outcome sets to inform regulatory authorities, health 
care providers and patients17. 
However, there is no empirical data with regards to PRO domains that most frequently differ 
between treatment arms in RCT settings. Such information could be critical in informing the 
ongoing discussion on the most relevant PRO domains to assess in clinical trials, and the design of 
future studies that include a PRO component.  
Our primary objective was to investigate which broad types of PRO domains (i.e., functional health 
vs. symptoms vs. global QoL) most often yield statistically significant differences between 
treatment arms in cancer RCTs. Secondary objectives were to evaluate the frequency of such 
differences for individual PRO domains (e.g. physical function, pain, and fatigue) and to evaluate 












We used the PROMOTION Registry19 to identify all cancer RCTs published between January 2004 
and February 2019 conducted in the most common cancer types20, i.e. breast, lung, colorectal, 
 
 
genitourinary, and gynaecological cancers. The PROMOTION Registry is a large database 
containing all RCTs published from 2004 across a wide range of cancer populations that included at 
least one PRO, either as a primary or secondary or exploratory endpoint. The trials were 
systematically identified, mainly through PubMed/Medline, and using ad-hoc key searching 
strategies for each cancer disease site. We included RCTs that enrolled a minimum of 50 patients 
and that reported at least one PRO endpoint. Trials comparing screening programs, 
complementary/alternative medicines and psychosocial interventions were excluded. Details on the 
search strategy and selection process were documented according to the Preferred Reporting Items 
for Systematic Reviews and Meta-analysis guidelines (PRISMA)21. 
For each trial selected, two trained reviewers independently extracted information. When 
disagreement about data extraction occurred, the two reviewers revisited the paper to reconcile any 
differences and, if necessary, a third reviewer was consulted to resolve any outstanding discrepancy 
and reach consensus. Each reviewer had a personal password to access the study website 
(REDCap22) and complete a pre-defined electronic data extraction form.  
Data extracted from each RCT included: (1) basic trial information (e.g. study location, sample size, 
disease stage, type of treatments being compared); (2) quality of PRO reporting, based on the 
International Society for Quality of Life Research (ISOQOL) recommended standards23; and (3) 
PRO instruments used and type of PRO outcomes that yielded statistically significant differences 
between trial arms.  
 
Outcomes definition and variables examined  
Among the generic-cancer PRO instruments that are most frequently used for treatment outcome 
comparisons in RCT settings, only the multidimensional EORTC QLQ-C30 questionnaire24 makes 
a clear distinction between three broad types of PRO domains: 1) Functional health;  2) Symptoms; 
and 3) Global health status/HRQoL. Other commonly used generic-cancer PRO questionnaires used 
 
 
in RCTs do not cover all broad types of PRO domains. Therefore, for the purpose of this study, we 
only considered RCTs using the EORTC QLQ-C30 questionnaire. As our goal was not to evaluate 
the appropriateness of PRO domain selection in relation to the specific research questions posed in 
any given trial, we focused on examining the prevalence of statistically significant differences 
(where applicable) between treatment arms across all domains reported in the publication.  
The EORTC QLQ-C3024 comprises 30 items that cover 15  individual domains: Physical, Role, 
Social,  Emotional and Cognitive functioning, Fatigue, Pain, Nausea/Vomiting, Appetite Loss, 
Dyspnoea, Sleep Disturbances, Diarrhoea, Constipation, Financial difficulties and Global Health 
Status/QoL (for the remaining of this article refereed to Global QoL). We have further grouped 
these individual domains into 3 broad categories: (1) Functional health (i.e., Physical, Role, Social, 
Emotional, and Cognitive functioning); (2) Symptoms (i.e., Fatigue, Pain, Nausea/Vomiting, 
Appetite Loss, Dyspnoea, Sleep Disturbances, Diarrhoea, and Constipation); and (3) Global QoL. 
The Financial difficulties domain was excluded from our analysis as it is distinct from these three 
broad types of PRO domains.  
We also recorded information on individual PRO domains that yielded statistically significant 
differences between arms at any time point during the trial and then categorized the type of 
statistically significant outcomes observed as: 1) Functional health outcomes only; 2) Symptoms 




We used absolute frequencies and proportions to describe the main characteristics of studies and to 
assess the prevalence of statistically significant differences between treatment arms in broad types 
of PRO domains, as defined above. A difference for a broad type of PRO domain was stated, if at 
 
 
least one individual PRO domain within that broad type differed between treatment arms. For more 
detailed information, we also provide descriptive statistics at the level of individual domains. 
To account for possible selective PRO outcome reporting, we also performed separate analyses for 
studies reporting an a priori PRO hypothesis for one or more specific domains versus those that did 
not. The same approach was adopted to investigate the prevalence of differences in individual PRO 
domains, overall, by cancer site (breast, lung, colorectal, gynaecological and genitourinary) and 
disease stage across cancer sites (non-metastatic vs metastatic). When assessing prevalence by 
disease stage, we excluded those studies whose samples included heterogeneous disease stage.  
We assessed the quality of reporting of each RCT using the ISOQOL recommended criteria,23 
which are amongst the most comprehensive and highest quality criteria for the rigorous reporting of 
PROs in RCTs and were also the basis for the development of the CONSORT (CONsolidated 
Standards Of Reporting in Trials) PRO extension25. Based on previous work26, each item of the 
ISOQOL criteria was scored “1” if reported and “0” if not, therefore, each trial received a maximum 
score of 18 (when the PRO was a secondary endpoint) and 29 (when the PRO was a primary 
endpoint). The ISOQOL checklist score was then divided by the maximum number of relevant 
items and multiplied by 100 to obtain a score ranging from 0 (worst quality) to 100 (best quality).  
For each QLQ-C30 domain, we used multivariable logistic regression analysis, with the reported 
statistically significant difference between trial arms (yes vs. no) as the dependent variable and the 
ISOQOL checklist score (continuous) as the main independent variable. The analyses were adjusted 
for key study characteristics that we expected to possibly influence PRO outcomes. These included 
: international setting of the study (yes vs. no), being industry supported (yes vs. no), sample size 
(n>200 vs. n≤200),whether PROs were the primary trial outcome (yes vs. no) and study design 
(open-label vs. blinded trials). We report the corresponding odds ratios and 95% confidence 
intervals per 10-point increase in the ISOQOL checklist score. All statistical tests were two-sided 
 
 
and statistical significance was set as α=0.05. All analyses were performed with SAS software v.9.4 






Characteristics of clinical trials included in the analysis 
Of the 649 RCTs included in the PROMOTION Registry published between January 2004 and 
February 2019, 262 RCTs used the EORTC QLQ-C30 questionnaire. Of these, we excluded 33 
studies that did not report any information on statistical significance for any of the QLQ-C30 
domains or did not perform any statistical significance testing. Therefore, 229 RCTs, including a 
total of 126,262 patients, were included in the current analysis. Details on the selection process are 
reported in Figure 1. 
The majority of trials (n=170, 74.2%) enrolled more than 200 patients and nearly half of RCTs 
involved patients with metastatic disease (n=114, 49.8%). There were 182 open-label studies, 31 
blinded and 16 studies that were considered as unclear. Further details of RCTs are provided in 
Table 1. 
 
Insert Figure 1 and Table 1 
 
Prevalence of differences by broad type of PRO domains 
One hundred thirty-four trials (58.5%) reported statistically significant differences between 
treatment arms for at least one of the QLQ-C30 domains. The most commonly observed differences 
were reported for two or all three broad types of PRO domains (78 of 134 trials, 58.2%). In 35 trials 
(26.1%), significant differences were reported for Symptoms, Functional health, and Global QoL, in 
24 trials (17.9%) for Symptoms and Functional health, in 11 trials (8.2%) for Functional health and 
global QoL, and in 8 trials (6.0%) for Symptoms and Global QoL. 
If group differences were reported for only one broad type of PRO domain, these were most 
frequently reported for: Symptoms (33 trials, 24.6%), followed by Global QoL (14 trials, 10.5%) 
 
 
and Functional health (9 trials, 6.7%) (Figure 2). Prevalence of statistically significant differences 
between treatment arms was similar when considering RCTs reporting an a priori PRO hypothesis 
(N=27) versus those that did not (N=107). For example, the prevalence of differences reported for 
more than one type of PRO domains was the same, that is 58% of studies (data are reported in 
online supplementary Figure 1). 
 
Insert Figure 2 
 
Prevalence of differences for individual PRO domains  
Focusing on individual PRO domains, the five most frequently observed differences were for: 
Global QoL (29.7% of the trials), Physical Functioning (19.2%), Fatigue (18.8%), Nausea/Vomiting 
(18.3%), and Role Functioning (17.0%). In contrast, Constipation (8.7%) and Sleep Disturbances 
(10.5%) were least often observed as being significantly different between treatment arms (Table 2). 
Similar percentages were found by studies reporting an a priori hypothesis versus those that did not 
(data not shown). 
 
Insert Table 2 
 
In the 114 trials of patients with metastatic disease, the top three most frequent PRO differences 
were reported for: Global QoL (29.8%), Physical Functioning (23.7%) and Pain (19.3%). In the 68 
trials of non-metastatic patients, these were found for: Global QoL (27.9%), Fatigue (25.0%) and 
Social Functioning (23.5%). The most pronounced differences in PROs between trials of metastatic 
versus non-metastatic patients were found for Pain (8.8% of trials with differences in non-metastatic 
 
 
patients, vs 19.3% in metastatic patients), and Social Functioning (23.5% non-metastatic vs 13.2% 
metastatic) (Table 3).  
For descriptive purposes a comparison of prevalence of PRO differences by diagnostic group was 
also performed and results are reported in online supplementary Table 1. 
Insert Table 3 
Differences in individual  PRO domains by the quality of PRO reporting  
In a multivariable analysis, we investigated the association between the presence of statistically 
significant PRO differences in the RCTs and the quality of PRO reporting and found a statistically 
significant association in 6 out of the 14 QLQ-C30 domains analyzed.  
The top three strongest associations with quality of PRO reporting in terms of odds ratios (ORs) 
were observed for: Sleep Disturbances (OR 1.30, p=0.01), Nausea/Vomiting (OR=1.25, p=0.01) 
and Cognitive Functioning (OR 1.24, p=0.03). No significant association was found between 
Global QoL and the quality of PRO reporting (OR=1.00, p=0.98) (Table 4).  
The likelihood of finding a statistically significant difference between treatment arms was not 
associated with RCT study design (i.e., open-label vs. blinded trials), industry support, type of PRO 
endpoint (primary vs. secondary) and study location (international vs. national) for any of the 14 
individual PRO domains analyzed. 




In approximately 60% of the oncology RCTs reviewed, there was a significant PRO difference 
between treatment arms, and these differences were reported for two or three broad types of PRO 
domains, i.e. Functional health and/or Symptoms, and/or Global QoL. Also, the top three individual 
 
 
PRO domains differing most frequently between treatment arms across all RCTs were: Global QoL, 
Physical Functioning and Fatigue.  
Our results build on previous work concerned with the choice of PRO domains to be used as 
endpoints in cancer trials. As noted earlier, the NCI-driven initiative to harmonize trial outcomes14 
recommended a core set of 12 patient-reported symptoms for cancer trials based on a literature 
review, data from clinical trials and a consensus process. Following this, the FDA12,16 has 
recommended that PROs focus on symptomatic adverse events, disease-related symptoms and 
measures of physical function. In contrast, the value added by broad concepts such as HRQoL and 
psychosocial domains, has been questioned as being too distal from the core business of cancer 
treatment, and thus of cancer clinical trials12 (i.e., that these domains may be influenced by factors 
not directly related to cancer treatment, resulting in low sensitivity to treatment effects). However, 
we found that functional health domains and Global QoL were among the PROs that most often 
yielded statistically significant differences between treatment arms in oncology RCTs. Thus, our 
analysis provides empirical evidence for the sensitivity of functional health outcomes and Global 
QoL, and hence our findings challenge the assumption that such outcomes are too distal to be of 
sustained value in trial-based PRO assessments. 
Our findings broadly support the approach taken by the EMA between 2012 and 2016 for approving 
PRO labelling in oncology treatments1. For about three-quarters of indications, such labelling 
mentioned symptom domains, while two-thirds referred to broad concepts such as global health 
status or QoL. Interestingly, no PRO labelling was granted by the FDA for cancer drugs in the same 
period, with FDA concerns mostly related to study design, magnitude of differences between 
treatment arms, validity of the measures, and missing data1. Across all medical fields, the FDA has 
approved PRO-related labelling claims less often than the EMA, and those claims granted were 
mostly related to symptoms. In contrast, the EMA has more frequently approved QoL claims27. The 
different regulatory policies of the EMA and FDA reflect the ongoing discussion of what PRO 
 
 
domains to measure in cancer trials, and consequently what information should be made available 
to regulatory authorities, health care providers and patients.  
Although we did not observe a significant association between the quality of PRO reporting and the 
likelihood that they would yield differences in Global QoL, this was the case for a number of 
functional health and symptom domains. Specifically, RCTs with lower quality of PRO reporting 
tended to yield fewer significant PRO outcomes. This suggests that in trials with low quality 
reporting, real differences in certain PRO domains may be underreported, resulting in an 
underestimation of the impact of trial-based treatments on patients’ functioning and symptom 
burden (e.g., pain, fatigue and nausea). The finding that the prevalence of Global QoL differences 
was not associated with the quality of reporting may indicate that this domain is less prone to 
underreporting than the other domain, which may explain in part the higher frequency of observed 
differences for this domain. Underreporting of PRO data from oncology RCTs has been identified 
as a major problem in a previous study by Kyte et al.28 who showed that about one-third of trials fail 
to publish their PRO results at all. Our analysis further extends this previous analysis by indicating 
that even if PRO results from a trial are published, the reporting of actual PRO results may be 
incomplete and selective.   
We also found that some key RCT characteristics, such as industry support or open-label vs. 
blinded trials, were not associated with the likelihood finding a statistically significant difference 
between treatment arms. For example, despite  some concerns expressed by regulators with regard  
to the potential bias of PRO results stemming from open-label trials1, our findings do not seem to 
support this view. While there is paucity of empirical data in this area, and more in depth and 
comprehensive analyses are needed to fully consider the impact of blinding on PRO results, our 
current findings are in line with a recent structured review by Atkinson and colleagues29, who 
concluded that inadvertent unblinding should not be considered as a meaningful source of bias. 
 
 
Since the focus of our study was on the comparison of broad types of PRO domains, we restricted 
our analysis to those trials using the QLQ-C30, as this is the only measure that distinguishes clearly 
between functional health, symptoms and Global QoL, thus allowing such a thorough comparison 
of these three broad types of PRO domains. Due to the widespread use of the QLQ-C30, we could 
still include a large number of trials covering the main cancer diagnoses in our analysis. Assuming 
that the trials using the QLQ-C30 do not differ systematically from other trials, we think that our 
findings can be generalized and are not affected by a selection bias regarding trial setting.  
Our analysis has several limitations. We relied on statistically significant differences between 
treatment arms and did not investigate the clinical relevance of the observed differences. However, 
we did not attempt such an evaluation as this would have been very difficult given the range of 
approaches and lack of consensus on how best to define and assess clinical significance30. Also, 
despite the fact that our analysis of prevalence of differences in studies reporting an a priori PRO 
hypothesis versus those that did not, confirmed that PRO differences were similar across multiple 
broad types of PRO domains, we cannot rule out the possibility that some trials used a selective 
approach by only reporting a subset of PRO domains, even though a priori hypotheses were posed 
in the manuscript.  
Conclusions 
In conclusion, we report the first evidence-based information regarding the frequency and the type 
of PRO differences that are observed between treatment arms in oncology RCTs. In most trials, 
such differences are typically reported for combinations of functional health, symptoms, and Global 
QoL, thereby highlighting the importance of a multidimensional approach to PRO assessment to 





1. Gnanasakthy A, Barrett A, Evans E, D'Alessio D, Romano CD. A Review of Patient-
Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA 
(2012-2016). Value Health. 2019;22(2):203-209. 
2. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence 
supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311(4):368-
377. 
3. US Department of Health and Human Services Food and Drug Administration. Guidance for 
industry: patient-reported outcome measures: use in medical product development to support 
labeling claims. 2009. Accessed May 6, 2019  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidanc
es/UCM193282.pdf  
4. Efficace F, Fayers P, Pusic A, et al. Quality of patient-reported outcome reporting across 
cancer randomized controlled trials according to the CONSORT patient-reported outcome 
extension: A pooled analysis of 557 trials. Cancer. 2015;121(18):3335-3342. 
5. LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care - hearing the patient 
voice at greater volume. Nat Rev Clin Oncol. 2017;14(12):763-772. 
6. Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 
2013;369(5):397-400. 
7. Kluetz PG, O'Connor DJ, Soltys K. Incorporating the patient experience into regulatory 
decision making in the USA, Europe, and Canada. Lancet Oncol. 2018;19(5):e267-e274. 
8. Velikova G, Stark D, Selby P. Quality of life instruments in oncology. Eur J Cancer. 
1999;35(11):1571-1580. 
9. Soni MK, Cella D. Quality of life and symptom measures in oncology: an overview. Am J 
Manag Care. 2002;8(18 Suppl):S560-573. 
10. European Medicine Agency. The use of patient-reported outcome (PRO) measures in 
oncology studies. Appendix 2 to the guideline on the evaluation of anticancer medicinal 
products in man. 2016. 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC500205159.pd
f Accessed July 9, 2017  
11. Groenvold M, Aaronson NK, Darlington AE, et al. Focusing on Core Patient-Reported 
Outcomes in Cancer Clinical Trials-Letter. Clin Cancer Res. 2016;22(22):5617. 
12. Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on Core Patient-Reported Outcomes 
in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-
Related Symptoms. Clin Cancer Res. 2016;22(7):1553-1558. 
13. Basch E, Geoghegan C, Coons SJ, et al. Patient-Reported Outcomes in Cancer Drug 
Development and US Regulatory Review: Perspectives From Industry, the Food and Drug 
Administration, and the Patient. JAMA Oncol. 2015;1(3):375-379. 
14. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of 
symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7). 
15. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported 
outcomes. J Natl Cancer Inst Monogr. 2007(37):16-21. 
16. Kluetz PG, Papadopoulos EJ, Johnson LL, et al. Focusing on Core Patient-Reported 
Outcomes in Cancer Clinical Trials-Response. Clin Cancer Res. 2016;22(22):5618. 
17. US Food and Drug Administration. FDA-ASCO Public Workshop: 2019 Clinical Outcome 
Assessments in Cancer Clinical Trials Fourth Annual Workshop. 
https://www.fda.gov/drugs/news-events-human-drugs/fda-asco-public-workshop-2019-




18. Kluetz PG, Kanapuru B, Lemery S, et al. Informing the Tolerability of Cancer Treatments 
Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute 
Workshop. Value in health : the journal of the International Society for 
Pharmacoeconomics and Outcomes Research. 2018;21(6):742-747. 
19. Efficace F, Rees J, Fayers P, et al. Overcoming barriers to the implementation of patient-
reported outcomes in cancer clinical trials: the PROMOTION Registry. Health Qual Life 
Outcomes. 2014;12:86. 
20. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, 
Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International 
Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed (June 
24, 2019). 
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-341. 
22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data 
capture (REDCap)--a metadata-driven methodology and workflow process for providing 
translational research informatics support. J Biomed Inform. 2009;42(2):377-381. 
23. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical 
trials: development of ISOQoL reporting standards. Qual Life Res. 2013;22(6):1161-1175. 
24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and 
Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical 
trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. 
25. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of 
patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 
2013;309(8):814-822. 
26. Efficace F, Feuerstein M, Fayers P, et al. Patient-reported Outcomes in Randomised 
Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical 
Decision Making. Eur Urol. 2014;66(3):416-427. 
27. DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO 
label claims granted by the FDA as compared to the EMA (2006-2010). Value Health. 
2013;16(8):1150-1155. 
28. Kyte D, Retzer A, Ahmed K, et al. Systematic evaluation of Patient-Reported Outcome 
protocol content and reporting in cancer trials. J Natl Cancer Inst. 2019. 
29. Atkinson TM, Wagner J-S, Basch E. Trustworthiness of Patient-Reported Outcomes in 
Unblinded Cancer Clinical Trials. JAMA oncology. 2017;3(6):738-739. 
30. Ousmen A, Touraine C, Deliu N, et al. Distribution- and anchor-based methods to determine 
the minimally important difference on patient-reported outcome questionnaires in oncology: 






Table 1: Characteristics of cancer clinical trials included in the analysis (N=229)  
Trial characteristic  N  % 
International (if more than one country) No 134  58.5 
  Yes 95  41.5 
Industry supported (fully or in part) No 99  43.2 
  Yes 130  56.8 
Disease stage Metastatic 114  49.8 
 
Non-metastatic 68  29.7 
 
Both 37  16.2 
  Unclear 10  4.3 
Overall study sample size ≤200 59  25.8 
  >200 170  74.2 
Year of publication 2004-2010 127  55.5 
  2011-2019 102  44.5 
Secondary paper on PRO No 155  67.7 
  Yes 74  32.3 
Type of treatment* Radiotherapy 36  15.7 
 
Surgery 23  10.0 
 
Chemotherapy 148  64.6 
 
Targeted therapy 39  17.0 
 
Hormonal therapy 27  11.8 
  Other 26  11.4 



















 N % 
Functioning domains     
Physical Functioning 44 19.2% 
Role Functioning 39 17.0% 
Social Functioning 37 16.2% 
Emotional Functioning 31 13.5% 
Cognitive Functioning 25 10.9% 
Global Quality of Life 68 29.7% 
Symptom domains    
Fatigue 43 18.8% 
Pain 35 15.3% 
Nausea/Vomiting 42 18.3% 
Sleep Disturbances 24 10.5% 
Dyspnoea 30 13.1% 
Appetite Loss 33 14.4% 
Constipation 20 8.7% 
Diarrhoea 33 14.4% 
 
RCT: randomized controlled trials. 




Table 3: Results from trials including EORTC QLQ-C30 domains as study endpoints in 
patients with non-metastatic (68 trials) and metastatic (114 trials) disease 
 
 Differences between treatment arms 
QLQ-C30 domains Non-metastatic Metastatic 
 N % N % 
Functioning domains     
Physical Functioning 10 14.7% 27 23.7% 
Role Functioning 13 19.1% 20 17.5% 
Social Functioning 16 23.5% 15 13.2% 
Emotional Functioning 8 11.8% 17 14.9% 
Cognitive Functioning 8 11.8% 13 11.4% 
Global Quality of Life 19 27.9% 34 29.8% 
Symptom domains     
Fatigue 17 25.0% 20 17.5% 
Pain 6 8.8% 22 19.3% 
Nausea/Vomiting 12 17.7% 21 18.4% 
Sleep Disturbances 11 16.2% 11 9.7% 
Dyspnoea 9 13.2% 17 14.9% 
Appetite Loss 11 16.2% 15 13.2% 
Constipation 7 10.3% 11 9.7% 








Table 4: Association between quality of PRO reporting and prevalence of differences for  individual PRO domains 
 Fatigue Pain Nausea/Vomiting Sleep disturbances Dyspnoea Appetite loss  Constipation Diarrhoea 
 












































































































































 Global QoL Physical Functioning Role Functioning Social Functioning Emotional Functioning Cognitive Functioning 
 
OR  (95% CI) P value OR  (95% CI) P value OR  (95% CI) P value OR  (95% CI) P value OR  (95% CI) P value OR  (95% CI) P value 


















































































1OR (odds ratios) are given per 10 points on the quality metric; values above 1 indicate a higher frequency of differences in high-quality trials (i.e. lower frequency in low quality 




Figure 1: Schematic breakdown of literature search results of Randomised Controlled 
Trials (Preferred Reporting Items for Systematic Reviews and Meta-analysis). 
 
Figure 2: Differences between treatment arms in cancer RCTs (N=134) by broad type of 
PRO domain 
Legend: Percentages refer to the total number of RCTs using the EORTC QLQ-C30 with 
significant differences (N=134) 
 
 
